Fangzhou Publishes 2025 Annual Report, Advancing AI-Powered Chronic Care Strategy for 2026 [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
AI-driven Internet healthcare solutions, published its 2025 Annual Report, following the announcement of its 2025 annual results on March 19, 2026. The report highlights strong revenue growth, a return to full-year profitability and continued execution of Fangzhou's “AI + chronic care” strategy as the Company advances its position as a trusted, long-term healthcare service partner for chronic disease patients across China. Revenue rose 30.2% year on year to RMB 3.53 billion, while net profit reached RMB 12 million, highlighting improving operating leverage. This performance underscores the resilience and scalability of Fangzhou's business model and provides a solid foundation for further investment in AI-enabled chronic disease services and platform upgrades. In 2025, Fangzhou upgraded its H2H (Hospital-to-Home) ecosystem with an “AI + H2H” architecture powered by its proprietary “XingShi” Large Language Model (“XS LLM”). By embedding AI capabilities across key service and operation
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk Rare Disease Wins Add Context To Undervalued Share Price [Yahoo! Finance]Yahoo! Finance
- Is This Deal a Game Changer for Novo Nordisk? [Yahoo! Finance]Yahoo! Finance
- Is This Deal a Game Changer for Novo Nordisk? [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- GLP-1 pill race heats up as Wegovy tablet holds strong against Lilly rival [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 4/27/26 - Form 6-K
- 4/20/26 - Form 6-K
- 4/20/26 - Form 6-K
- NVO's page on the SEC website